Haematopoietic Stem Cell Treatment

ChangeBridge: Patent Grants - Biotech (C12N)

Published March 31st, 2026

Detected March 31st, 2026

Summary

The USPTO granted patent US12589115B2 to the University of Edinburgh on March 31, 2026. The patent covers modified haematopoietic stem cells (HSCs), methods for preparing them, and their therapeutic applications including treatment of haematological disorders. A particular focus is on methods for treating conditions characterized by elevated YTHDF2 expression using YTHDF2 inhibitors. Seven claims were issued.

View original document View source feed page

What changed

The USPTO issued patent US12589115B2 to the University Court of the University of Edinburgh for inventions related to modified haematopoietic stem cells. The granted patent includes 7 claims covering methods of preparing modified HSCs, their use in therapy, methods for expanding HSCs, and methods for treating haematological disorders including conditions with elevated YTHDF2 expression. Inventors are Kamil Romuald Kranc and Dónal O'Carroll.

This is a routine patent grant creating intellectual property rights for the assignee. Third parties are not required to take compliance action but should conduct freedom-to-operate analyses if developing competing stem cell therapies. Entities interested in licensing the technology may contact the University of Edinburgh's technology transfer office.

Source document (simplified)

← USPTO Patent Grants

Haematopoietic stem cell treatment

Grant US12589115B2 Kind: B2 Mar 31, 2026

Assignee

THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH

Inventors

Kamil Romuald Kranc, Dónal O'Carroll

Abstract

The present invention relates to modified haematopoietic stem cells, methods for preparing them, and their use in therapy; as well as methods and reagents for expanding haematopoietic stem cells (HSC) and methods for treating haematological disorders. A particular aspect relates to a method for treating a disease or condition characterised by elevated YTHDF2 expression comprising administering to a patient an effective amount of an YTHDF2 inhibitor. Certain aspects of the invention rely on YTFIDF2 protein level or function and use of YTFIDF2 inhibitors.